{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:17:24Z","timestamp":1791062244199,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T00:00:00Z","timestamp":1269907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>This international, non\u2010randomised study evaluated maintained efficacy and safety of Risperidone Long\u2010Acting Injectable (RLAI) compared to previous medications. To investigate the possible effect of differences in national health care systems across Europe, the UK subset efficacy, health\u2010related quality of life (HRQoL) and functioning data are reported here.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with schizophrenia or other psychotic disorders, symptomatically stable on antipsychotic medication, received intramuscular injections of RLAI 25\u2009mg (to a maximum of 50\u2009mg) every 2 weeks for 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 182 UK patients recruited; 79% had schizophrenia (87% paranoid), 21% other psychotic disorders; 96% had been hospitalised at sometime. Improvement in mean Positive and Negative Syndrome Scale (PANSS) total score was significant at 1 month through to endpoint (<jats:italic>p<\/jats:italic>\u2009=\u20090.0001). There were significant improvements in PANSS subscales (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.001), PANSS\u2010Marder subscores (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.0391), and in Clinical Global Impression\u2010Severity (<jats:italic>p<\/jats:italic>\u2009=\u20090.0001) at endpoint. Patients reported improvements in: HRQoL (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), Global Assessment of Functioning (<jats:italic>p<\/jats:italic>\u2009=\u20090.0001) and patient satisfaction (<jats:italic>p<\/jats:italic>\u2009=\u20090.0001) at endpoint. The proportion of patients rating RLAI treatment as \u2018very good\u2019 increased from 10% to 40%. 55% (22\/40) of patients hospitalised at baseline were discharged by endpoint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Sustained, significant improvement in symptom control, HRQoL and functioning was seen in stable patients treated with RLAI over 6 months following a switch from previous antipsychotic medications. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.1108","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T15:55:49Z","timestamp":1269964549000},"page":"243-252","source":"Crossref","is-referenced-by-count":24,"title":["Switching stable patients with schizophrenia from depot and oral antipsychotics to long\u2010acting injectable risperidone: efficacy, quality of life and functional outcome"],"prefix":"10.1002","volume":"25","author":[{"given":"Keith","family":"Lloyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammud A.","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshar L.","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,30]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1994.tb05828.x"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta7130"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199410060-00005"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199511000-00001"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.07.003"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa002028"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.146.5.469"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.6.553"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447050-00004"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523001-00004"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523030-00009"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2003.11.001"},{"issue":"16","key":"e_1_2_1_15_1","first-page":"18","article-title":"Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics","volume":"64","author":"Ereshefsky L","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1017"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.2.131"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7273.1371"},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","unstructured":"GuyW.1976.ECDEU Assessment manual for psychopharmacology. Revised. Rockville Maryland USA: US Department of Health Education and Welfare 217\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418020-00005"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1085"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.53.1.46"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00059-1"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.6.1125"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1105"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0121"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.12.009"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.978"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00105-4"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0809"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46014"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1205"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17215"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2005.03.006"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200505000-00001"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00980.x"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0412"},{"key":"e_1_2_1_40_1","volume-title":"Schizophrenia. Full National Clinical Guideline on Core Interventions in Primary and Secondary Care","author":"National Institute for [Health and] Clinical Excellence","year":"2003"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0808"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199907000-00008"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007076"},{"key":"e_1_2_1_44_1","unstructured":"WareJ SnowK KosinskiM.1993.SF\u201036 Health Survey Manual and Interpretation Guide. Boston Massachusetts. The Health Institute."},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.8.886"},{"key":"e_1_2_1_46_1","first-page":"106","article-title":"Medication noncompliance in Schizophrenia, Pt 1: assessment","author":"Weiden J","year":"1997","journal-title":"J Pract Psychiatry Behav Healt"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00766.x"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1108","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:56:42Z","timestamp":1700557002000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,30]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1002\/hup.1108"],"URL":"https:\/\/doi.org\/10.1002\/hup.1108","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,30]]}}}